Home / Health / Weight Loss Drugs Cut Cancer Risk by 30%
Weight Loss Drugs Cut Cancer Risk by 30%
2 Jun
Summary
- Weight-loss drugs may reduce cancer development or death by 30%.
- Studies presented at a major oncology conference suggest these drugs' potential.
- GLP-1 medications mimic hormones regulating appetite and blood sugar.
Weight-loss medications are showing remarkable potential in combating cancer, with studies indicating they could cut the risk of developing or dying from the disease by as much as 30%. These findings, presented at the American Society of Clinical Oncology's annual meeting, are based on analyses of GLP-1 medications, a class of drugs that mimic natural hormones influencing blood sugar and appetite.
One analysis revealed that women taking GLP-1 medications had a 30% lower likelihood of developing breast cancer. Furthermore, adding these drugs to standard treatment for existing breast cancer was linked to a 30% decrease in the risk of death. The research also suggested a significant reduction, between 38% and 50%, in the likelihood of advanced-stage disease in patients with lung, breast, bowel, or liver cancer.
While researchers are exploring the mechanisms behind these effects, including anti-inflammatory properties and other metabolic influences beyond just weight loss, experts emphasize the need for further studies. The potential for these drugs to also mitigate treatment side-effects is also being investigated, marking a rapidly evolving area of cancer research.
